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rates: 1.15 and 1.51 for 1A and 1B respectively, p < 0.01).
Mean (SD) costs of care at one year of follow-up also
were reduced among GA patients ($9,522 [$9,706] vs.
$9,957 [$9,083] and $10,185 [$9,526] for 1A and 1B
respectively). Findings persisted in multivariate analyses
controlling for differences in demographic characteristics
and propensity scores for immunomodulatory therapy.
CONCLUSIONS: Glatiramer acetate is associated with
reductions in the incidence of relapse and costs of care
relative to the beta interferons among this large group of
managed-care patients with MS.
NEUROLOGICAL DIESEASES/DISORDERS &
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The Total Outcome of Pain Scale, TOPS, is a fully vali-
dated disease-speciﬁc outcome measurement tool for use
in patients with chronic pain. The TOPS provides much
greater sensitivity and speciﬁcity for measuring outcomes.
The 60°V-item TOPS questionnaire contains the SF-36
and information on Pain Symptom, Functional 
Limitations, Perceived Family/Social Disability, Real
Family/Social Disability and Formal Work Disability.
Unlike the SF-36, TOPS is precise enough to monitor
outcome over time in individual patients. All patients at
the University of Utah Pain Management Center complete
TOPS at evaluation, three months, six months, and then
every six months for the duration of therapy. Paper forms
are scanned into an Access database. This produces a
report that summarizes current and prior TOPS scores for
the patient and which is put into the patient’s medical
record. From July 1, 1997 through August 2, 2001, 3454
TOPS instruments were completed and entered. This rep-
resented 2692 individual patients. Most (80.5%) of
patients completed one TOPS; the remainder had 2 or
more. This population was 62.2% female and had the fol-
lowing characteristics (median values): age (40–44), years
of education (13), income $30,000–$39,999. The 6 most
common diagnoses and ICD 9 codes were: myalgia and
myositis, unspeciﬁed (729.11, low back pain, low back
syndrome (724.2), pain in limb (729.5), neuralgia, neuri-
tis, and radiculitis, unspeciﬁed (729.2), cervicalgia, pain
in neck (723.1) and headache (784.0). Mean responses
were as follows: ICD 9 Code PCS MCS Pain Symptom
Score Work Disability 729.1 28.9 39.7 72.2 37.7 724.2
27.1 40.1 72.9 47.4 729.5 27.9 40.4 75.3 38.7 729.2
28.9 40.1 73.0 46.8 723.1 30.5 37.6 73.2 40.1 784.0
31.6 37.6 71.2 31.8. Data collection is ongoing, with
20–30 surveys completed weekly. By the end of 2002,
data on approximately 5000 TOPS administrations will
be available and will be included in the presentation.
Querying the database may provide valuable data on rel-
ative outcomes by intervention and clinician.
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OBJECTIVES: To determine rate of adoption of saliva
concentrations as a monitoring method for antiepileptic
drugs (AEDs). To determine whether child neurologists
would prefer saliva testing to serum testing to obtain 
AED concentrations for clinical practice. METHODS:
A survey asked participants about use, availability, and
value to the physician of saliva AED concentrations.
Respondents chose between the following four responses
when considering value: 1) Very valuable, willing to
spend 1/2 hour of time per patient to arrange; 2) Moder-
ately valuable, willing to spend 10 minutes of time per
patient to arrange; 3) Not very valuable, might use test
but would not spend extra time to arrange; and 4) Of no
special value, I doubt that I would use such a test. All
members of the Child Neurology Society were surveyed.
Surveys were re-mailed to non-responders after one- and
two-month intervals. RESULTS: We mailed 1006 surveys
and received 546 responses (54%) and 57 surveys were
returned undelivered. Less than 1% of respondents had
obtained a saliva AED concentration in the last year.
Seven percent stated there was an available laboratory to
perform saliva AED concentration determinations. Fifty-
three percent of individuals indicated that having a pain-
free method of AED concentration determination was
very or moderately valuable to them and 68% stated that
the ability to obtain real-time samples outside of the clin-
ical environment was very or moderately valuable. CON-
CLUSIONS: Most child neurologists have not obtained
saliva AED concentrations and perceive they do not have
this technology available to them. The majority of respon-
dents would be willing to spend 10–30 minutes of time
to arrange for saliva AED concentrations to prevent
patient discomfort and obtain real-time concentrations.
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OBJECTIVES: The growing attention to the social aspect
of epilepsy and the necessity to improve the system of 
care require knowledge of QOL and pharmacoeconomic
